CAR-T（CAR-T）细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CAR-T（CAR-T）细胞在血液系统恶性肿瘤中的应用推动了这种免疫治疗形式的显著进展。
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
弥漫性内生型脑桥胶质瘤和 CAR-T 细胞治疗：新兴前沿
英文原题：Diffuse Intrinsic Pontine Glioma and Chimeric Antigen Receptor T-Cell Therapy: An Emerging Frontier.
查看英文原题
Diffuse Intrinsic Pontine Glioma and Chimeric Antigen Receptor T-Cell Therapy: An Emerging Frontier.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
本研究探索CAR-T 细胞疗法联合对流增强递送（CED），作为治疗弥漫性内生性脑桥胶质瘤这一侵袭性极强、治疗选择有限的儿童脑肿瘤的新方法。初步临床结果显示，CED可改善CAR-T 细胞在肿瘤微环境中的分布，带来有前景的抗肿瘤应答。但导管相关并发症及潜在靶向肿瘤外毒性仍是挑战。仍需持续研究以优化这些策略，并解决与患者安全和创新疗法公平可及性相关的伦理问题。研究旨在评估通过CED直接递送至肿瘤部位的CAR-T 细胞之安全性、疗效和分布，从而在降低全身副作用的同时提高治疗结局。
展开英文摘要原文
This study explores the integration of chimeric antigen receptor T-cell (CAR-T) therapy with convection-enhanced delivery (CED) as a novel approach for treating diffuse intrinsic pontine glioma, a highly aggressive pediatric brain tumor with limited treatment options. Preliminary clinical results indicate that CED improves CAR-T cell distribution within the tumor microenvironment, leading to promising antitumor responses.
However, challenges such as catheter-related complications and potential on-target/off-tumor toxicity remain. Ongoing research is essential to optimize these strategies and address ethical considerations surrounding patient safety and equitable access to innovative therapies. The aim is to assess the safety, efficacy, and distribution of CAR T cells delivered directly to the tumor site via CED, thereby enhancing therapeutic outcomes while minimizing systemic side effects.
论文信息
- 作者
- Tykocki T
- 单位
- Department of Paediatric Neurosurgery, Children's Hospital named after Prof. Jan Bogdanowicz in Warsaw, Warsaw, Poland; Maria Sklodowska-Curie Medical Academy, Warsaw, Poland. Electronic address: ttykocki@gmail.com.Poland
- 文献类型
- 综述
- 期刊
- World neurosurgery2025 Feb
- 原文标识
- PubMed 39694135 · DOI 10.1016/j.wneu.2024.123579